Study title: Radiology. 1998 Oct;209(1):253-8. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Neoplasms [C04] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: FLUDEOXYGLUCOSE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |